Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.

Filiaciones

Montesinos P:

Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.

CIBERONC, Instituto Carlos III, Madrid, Spain.

Roboz GJ:

Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine and The New York Presbyterian Hospital, New York, NY, USA

Bulabois CE:

CHU Grenoble, Service d'hématologie Clinique, Grenoble, France

Subklewe M:

Department of Medicine III, University Hospital Ludwig-Maximillians-Universität München, Munich, Germany

Platzbecker U:

Medical Clinic and Policlinic I, Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany

Ofran Y:

Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus and Technion Faculty of Medicine, Haifa, Israel

Papayannidis C:

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology and Medical Oncology "L. and A. Seragnoli", University of Bologna, Bologna, Italy

Wierzbowska A:

Department of Hematology, Medical University of Lodz, Lodz, Poland

Deneberg S:

Department of Hematology, Karolinska University Hospital, Stockholm, Sweden

Yeh SP:

Division of Hematology-Oncology, China Medical University Hospital, Taichung, Taiwan

Ozcan MA:

Department of Hematology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey

Knapper S:

Cardiff University School of Medicine, Cardiff, UK

Cortes J:

Department of Leukemia, MD Anderson Cancer Center, Houston, TX, USA

Pollyea DA:

Division of Hematology, School of Medicine, University of Colorado, Aurora, CO, USA

Giralt S:

Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Döhner H:

Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany

Heuser M:

Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

Xiu L:

Janssen Research and Development, Raritan, NJ, USA

Singh I:

Janssen Research and Development, Spring House, PA, USA

Huang F:

Janssen Research and Development, Spring House, PA, USA

Larsen JS:

Janssen Research and Development, Los Angeles, CA, USA

Wei AH:

Department of Haematology, The Alfred Hospital and Monash University, Melbourne, VIC, Australia